These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27726115)

  • 101. Pyruvate kinase: Function, regulation and role in cancer.
    Israelsen WJ; Vander Heiden MG
    Semin Cell Dev Biol; 2015 Jul; 43():43-51. PubMed ID: 26277545
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer.
    De Rosa V; Iommelli F; Monti M; Fonti R; Votta G; Stoppelli MP; Del Vecchio S
    Clin Cancer Res; 2015 Nov; 21(22):5110-20. PubMed ID: 26216352
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.
    Lee CK; Wu YL; Ding PN; Lord SJ; Inoue A; Zhou C; Mitsudomi T; Rosell R; Pavlakis N; Links M; Gebski V; Gralla RJ; Yang JC
    J Clin Oncol; 2015 Jun; 33(17):1958-65. PubMed ID: 25897154
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography.
    Iommelli F; De Rosa V; Gargiulo S; Panico M; Monti M; Greco A; Gramanzini M; Ortosecco G; Fonti R; Brunetti A; Del Vecchio S
    Clin Cancer Res; 2014 Sep; 20(18):4806-15. PubMed ID: 25052479
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Pyruvate kinase M2 and cancer: an updated assessment.
    Iqbal MA; Gupta V; Gopinath P; Mazurek S; Bamezai RN
    FEBS Lett; 2014 Aug; 588(16):2685-92. PubMed ID: 24747424
    [TBL] [Abstract][Full Text] [Related]  

  • 106. PKM2 contributes to cancer metabolism.
    Wong N; Ojo D; Yan J; Tang D
    Cancer Lett; 2015 Jan; 356(2 Pt A):184-91. PubMed ID: 24508027
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
    Ohashi K; Maruvka YE; Michor F; Pao W
    J Clin Oncol; 2013 Mar; 31(8):1070-80. PubMed ID: 23401451
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
    Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
    J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
    Kobe C; Scheffler M; Holstein A; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Dietlein M; Wolf J; Kahraman D
    Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1117-27. PubMed ID: 22526960
    [TBL] [Abstract][Full Text] [Related]  

  • 110. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer.
    Zannetti A; Iommelli F; Speranza A; Salvatore M; Del Vecchio S
    J Nucl Med; 2012 Mar; 53(3):443-50. PubMed ID: 22331221
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Crizotinib.
    Shaw AT; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Dec; 10(12):897-8. PubMed ID: 22129984
    [No Abstract]   [Full Text] [Related]  

  • 112. Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.
    Takahashi R; Hirata H; Tachibana I; Shimosegawa E; Inoue A; Nagatomo I; Takeda Y; Kida H; Goya S; Kijima T; Yoshida M; Kumagai T; Kumanogoh A; Okumura M; Hatazawa J; Kawase I
    Clin Cancer Res; 2012 Jan; 18(1):220-8. PubMed ID: 22019513
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.
    Zander T; Scheffler M; Nogova L; Kobe C; Engel-Riedel W; Hellmich M; Papachristou I; Toepelt K; Draube A; Heukamp L; Buettner R; Ko YD; Ullrich RT; Smit E; Boellaard R; Lammertsma AA; Hallek M; Jacobs AH; Schlesinger A; Schulte K; Querings S; Stoelben E; Neumaier B; Thomas RK; Dietlein M; Wolf J
    J Clin Oncol; 2011 May; 29(13):1701-8. PubMed ID: 21422426
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
    Mileshkin L; Hicks RJ; Hughes BG; Mitchell PL; Charu V; Gitlitz BJ; Macfarlane D; Solomon B; Amler LC; Yu W; Pirzkall A; Fine BM
    Clin Cancer Res; 2011 May; 17(10):3304-15. PubMed ID: 21364032
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
    Rosell R; Molina MA; Costa C; Simonetti S; Gimenez-Capitan A; Bertran-Alamillo J; Mayo C; Moran T; Mendez P; Cardenal F; Isla D; Provencio M; Cobo M; Insa A; Garcia-Campelo R; Reguart N; Majem M; Viteri S; Carcereny E; Porta R; Massuti B; Queralt C; de Aguirre I; Sanchez JM; Sanchez-Ronco M; Mate JL; Ariza A; Benlloch S; Sanchez JJ; Bivona TG; Sawyers CL; Taron M
    Clin Cancer Res; 2011 Mar; 17(5):1160-8. PubMed ID: 21233402
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.
    Pao W; Chmielecki J
    Nat Rev Cancer; 2010 Nov; 10(11):760-74. PubMed ID: 20966921
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.
    Zhou W; Ercan D; Chen L; Yun CH; Li D; Capelletti M; Cortot AB; Chirieac L; Iacob RE; Padera R; Engen JR; Wong KK; Eck MJ; Gray NS; Jänne PA
    Nature; 2009 Dec; 462(7276):1070-4. PubMed ID: 20033049
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
    Gazdar AF
    Oncogene; 2009 Aug; 28 Suppl 1(Suppl 1):S24-31. PubMed ID: 19680293
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Role of 18F-FDG PET in assessment of response in non-small cell lung cancer.
    Hicks RJ
    J Nucl Med; 2009 May; 50 Suppl 1():31S-42S. PubMed ID: 19380411
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Assessing tumor response to therapy.
    Weber WA
    J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.